Form 8-K - Current report:
SEC Accession No. 0001493152-25-011160
Filing Date
2025-03-21
Accepted
2025-03-21 17:00:24
Documents
13
Period of Report
2025-03-17
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38629
  Complete submission text file 0001493152-25-011160.txt   214085

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE tnfa-20250317.xsd EX-101.SCH 3018
3 XBRL LABEL FILE tnfa-20250317_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE tnfa-20250317_pre.xml EX-101.PRE 22361
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3837
Mailing Address 1185 AVENUE OF THE AMERICAS SUITE 249 NEW YORK NY 10036
Business Address 1185 AVENUE OF THE AMERICAS SUITE 249 NEW YORK NY 10036 856-848-8698
TNF Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36268 | Film No.: 25761413
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)